The Changing Face of Chronic Illness Management in Primary Care: A Qualitative Study of Underlying Influences and Unintended Outcomes

PURPOSE Recently, there has been dramatic increase in the diagnosis and pharmaceutical management of common chronic illnesses. Using qualitative data collected in primary care clinics, we assessed how these trends play out in clinical care. METHODS This qualitative study focused on management of type 2 diabetes and hypertension in 44 primary care clinics in Michigan and was based on interviews with 58 clinicians and 70 of their patients, and observations of 107 clinical consultations. We assessed clinicians’ treatment strategies and discussions of factors influencing treatment decisions, and patients’ understandings and experiences in managing these illnesses. RESULTS Clinicians focused on helping patients achieve test results recommended by national guidelines, and most reported combining 2 or more medications per condition to reach targets. Medication selection and management was the central focus of the consultations we observed. Polypharmacy was common among patients, with more than one-half taking 5 or more medications. Patient interviews indicated that heavy reliance on pharmaceuticals presents challenges to patient well-being, including financial costs and experiences of adverse health effects. CONCLUSIONS Factors promoting heavy use of pharmaceuticals include lower diagnostic and treatment thresholds, clinician-auditing and reward systems, and the prescribing cascade, whereby more medications are prescribed to control the effects of already-prescribed medications. We present a conceptual model, the inverse benefit law, to provide insight into the impact of pharmaceutical marketing efforts on the observed trends. We make recommendations about limiting the influence of the pharmaceutical industry on clinical practice, toward improving the well-being of patients with chronic illness.

[1]  Len Lichtenfeld,et al.  Overdiagnosed: Making People Sick in Pursuit of Health , 2011 .

[2]  M. S. Kirkman,et al.  Response to Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011, Diabetes Care.

[3]  Eric G Campbell,et al.  Conflicts of interest in cardiovascular clinical practice guidelines. , 2011, Archives of internal medicine.

[4]  Michael E. Miller,et al.  Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes , 2011 .

[5]  H. Brody,et al.  The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health , 2011, American journal of public health.

[6]  M. Rodwin Conflicts of Interest and the Future of Medicine: The United States, France, and Japan , 2011 .

[7]  Fang Zhang,et al.  Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom: interrupted time series study , 2011, BMJ : British Medical Journal.

[8]  R. Brumback White coat, black hat: Adventures on the dark side of medicine , 2011 .

[9]  M. Rodwin Comprar Conflicts of Interest and the Future of Medicine The United States, France, and Japan | Marc A. Rodwin | 9780199755486 | Oxford University Press , 2011 .

[10]  Sowmya R. Rao,et al.  Physician professionalism and changes in physician-industry relationships from 2004 to 2009. , 2010, Archives of internal medicine.

[11]  Mark Woodward,et al.  Severe hypoglycemia and risks of vascular events and death. , 2010, The New England journal of medicine.

[12]  Y. Ostchega,et al.  Recent trends in the prevalence of high blood pressure and its treatment and control, 1999-2008. , 2010, NCHS data brief.

[13]  Prevalence of selected risk behaviors and chronic diseases and conditions-steps communities, United States, 2006-2007. , 2010, Morbidity and mortality weekly report. Surveillance summaries.

[14]  C. Elliott White Coat, Black Hat: Adventures on the Dark Side of Medicine , 2010 .

[15]  Vicki L Burt,et al.  Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. , 2010, NCHS data brief.

[16]  Michael Oldani Assessing the ‘relative value’ of diabetic patients treated through an incentivized, corporate compliance model , 2010, Anthropology & medicine.

[17]  G. Bakris,et al.  Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. , 2010, JAMA.

[18]  Kalman D. Applbaum Shadow science: Zyprexa, Eli Lilly and the globalization of pharmaceutical damage control , 2010 .

[19]  M. Beach,et al.  Cryptosporidiosis surveillance - United States, 2006-2008. , 2010, Morbidity and mortality weekly report. Surveillance summaries.

[20]  J. Mold,et al.  The Law of Diminishing Returns in Clinical Medicine: How Much Risk Reduction is Enough? , 2010, The Journal of the American Board of Family Medicine.

[21]  R. Heine,et al.  Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study , 2010, The Lancet.

[22]  D. Light,et al.  3. The Commercialization of Medical Decisions: Physicians and Patients at Risk , 2010 .

[23]  D. Light 1. Bearing the Risks of Prescription Drugs , 2010 .

[24]  D. Light The risks of prescription drugs , 2010 .

[25]  Rodney A Hayward,et al.  New diabetes HEDIS blood pressure quality measure: potential for overtreatment. , 2010, The American journal of managed care.

[26]  V. Basevi Standards of Medical Care in Diabetes—2010 , 2010, Diabetes Care.

[27]  D. Aron,et al.  Hidden Complexities in Assessment of Glycemic Outcomes: Are Quality Rankings Aligned with Treatment? , 2010 .

[28]  S. Tanenbaum Pay for performance in Medicare: evidentiary irony and the politics of value. , 2009, Journal of health politics, policy and law.

[29]  Kalman D. Applbaum Getting to Yes: Corporate Power and the Creation of a Psychopharmaceutical Blockbuster , 2009, Culture, medicine and psychiatry.

[30]  R. Matthews Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry , 2008, Journal of Nuclear Medicine.

[31]  Sheila Leatherman,et al.  Lessons From Evaluations of Purchaser Pay-for-Performance Programs , 2008, Medical care research and review : MCRR.

[32]  Reamer L. Bushardt,et al.  Polypharmacy: Misleading, but manageable , 2008, Clinical interventions in aging.

[33]  Joel Lexchin,et al.  The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States , 2008, PLoS medicine.

[34]  J. Slinn Prescribing by Numbers: Drugs and the Definition of Disease , 2007 .

[35]  Bernard J. Gersh,et al.  Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention , 2007, Circulation.

[36]  T. Moger,et al.  Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. , 2007, British journal of clinical pharmacology.

[37]  J. Greene Prescribing by Numbers: Drugs and the Definition of Disease , 2007 .

[38]  B. Golomb,et al.  Physician Response to Patient Reports of Adverse Drug Effects , 2007, Drug safety.

[39]  H. Brody,et al.  Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry , 2006 .

[40]  T. Cymet,et al.  The Truth about Drug Companies: How They Deceive Us and What to Do about It , 2006 .

[41]  Lethia Collins Rn Msn Cnor Cfnp Overdo$ed America: The Broken Promise of American Medicine , 2006 .

[42]  J. Kassirer On the take : how America's complicity with big business can endanger your health , 2005 .

[43]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[44]  Ray Moynihan Overdo$ed America: The Broken Promise of American Medicine , 2004, BMJ : British Medical Journal.

[45]  J. Abramson Overdosed America: The Broken Promise of American Medicine , 2004 .

[46]  Marcia Angell,et al.  The Truth About the Drug Companies , 2004 .

[47]  Jerry Avorn,et al.  Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs , 2004 .

[48]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[49]  Ihab Hajjar,et al.  Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. , 2003, JAMA.

[50]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[51]  Andrea Ohldin,et al.  The search for value in health care: a review of the National Committee for Quality Assurance efforts. , 2002, Journal of the National Medical Association.

[52]  A. Detsky,et al.  Relationships between authors of clinical practice guidelines and the pharmaceutical industry. , 2002, JAMA.

[53]  B. Rockhill The privatization of risk. , 2001, American journal of public health.

[54]  S. Woolf,et al.  New diabetes guidelines: a closer look at the evidence. , 1998, American family physician.

[55]  Jerry H Gurwitz,et al.  Optimising drug treatment for elderly people: the prescribing cascade , 1997, BMJ.

[56]  Hj Norussis,et al.  SPSS for Windows , 1993 .

[57]  D. Commerce Statistical abstract of the United States , 1978 .